Efficacy and safety of chloroquine and hydroxychloroquine for COVID-19: A comprehensive evidence synthesis of clinical, animal, and in vitro studies

Farzaneh Barzkar1, Mitra Ranjbar2, Amir-Babak Sioofy-Khojine3, Mohammadamin Khajehazad4, Roya Vesal Azad4, Yousef Moradi5, Hamid Reza Baradaran*1,6

Received: 6 Oct 2020 Published: 17 Dec 2020

Abstract

Background: The world is facing a pandemic of COVID-19, a respiratory disease caused by a novel coronavirus which is now called SARS-CoV-2. Current treatment recommendations for the infection are mainly repurposed drugs based on experience with other clinically similar conditions and are not backed by direct evidence. Chloroquine (CQ) and its derivative Hydroxychloroquine (HCQ) are among the candidates. We aimed to synthesize current evidence systematically for in vitro, animal, and human studies on the efficacy and safety of chloroquine in patients with COVID-19.

Methods: The Cochrane Library, Google Scholar, PubMed (via Medline), Embase, Scopus, and Web of Science, MedRxiv, clinical trial registries including clinicaltrials.gov, ChiCTR (Chinese Clinical Trial Registry), IRCT (Iranian Registry of Clinical Trials), and the EU Clinical Trials Register. We used the Cochrane tool for risk of bias assessment in randomized studies, the ROBINS tool for non-randomized studies, and the GRADE methodology to summarize the evidence and certainty in effect estimates.

Results: The initial database searching retrieved 24,752 studies. Of these, 15,435 abstracts were screened and 115 were selected for full-text review. Finally, 20 human studies, 3 animal studies, and 4 in vitro studies were included in this systematic review. The risk of bias within studies was unclear to high and the overall certainty in evidence-based on GRADES- was very low. HCQ may be effective in clinical improvement in a subset of patients with COVID-19. However, the frequency of adverse events was higher in patients taking HCQ compared to standard of care alone. In contrast, animal studies, did not report any adverse effects. Furthermore, clear benefit of the drug in the survival of the animals has been reported. Most in vitro studies indicated a high selectivity index for the drug and one study that used a human coronavirus reported blockage of virus replication.

Conclusion: Current evidence background is limited to six poorly conducted clinical studies with inconsistent findings which fail to show significant efficacy for HCQ. Safety data is also limited but the drug may increase adverse outcomes. Routine use of the drug is not recommended based on limited efficacy and concerns about the drug safety especially in high-risk populations.

Keywords: Efficacy, Safety, Hydroxychloroquine, COVID-19, Systematic review

Conflicts of Interest: None declared

Funding: This study was financially supported by the Deputy of Research and Technology of Iran University of Medical Sciences, Tehran, Iran (Grant no. 17668).

*C This work has been published under CC BY-NC-SA 1.0 license.

Copyright© Iran University of Medical Sciences

Cite this article as: Barzkar F, Ranjbar M, Sioofy B, Khajehazad M, Vesal Azad Y, Moradi Y, Baradaran HR. Efficacy and safety of chloroquine and Hydroxychloroquine for COVID-19: A comprehensive evidence synthesis of clinical, animal, and in vitro studies. Med J Islam Repub Iran. 2020 (17 Dec);34:171. https://doi.org/10.47176/mjiri.34.171

Corresponding author: Dr Hamid Reza Baradaran, baradaran.hr@iums.ac.ir

1 Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran
2 Department of Infectious Diseases, School of Medicine, Iran University of Medical Science, Tehran, Iran
3 Department of Virology, Faculty of Medicine and Life Sciences, PL 100, 33014 University of Tampere, Tampere, Finland
4 School of Public Health, Iran University of Medical Sciences, Tehran, Iran
5 Social Determinants of Health Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran
6 Ageing Clinical & Experimental Research Team, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, Scotland, UK

†What is “already known” in this topic:
The world is facing a pandemic of COVID-19, so it is essential to survey in vitro, animal, and clinical evidence background for the effectiveness and safety of Hydroxychloroquine for treating patients with COVID-19 in around the world.

—What this article adds:
There is insufficient evidence to draw conclusions on the efficacy and safety of chloroquine and Hydroxychloroquine based on current evidence.
Introduction

From the black plague in the 14th century Europe to the cholera pandemics of the 19th century and the 1918 Spanish flu, epidemics have always been a subject of concern and a cause of mass mortality as well as considerable economic, social, and psycho logic harm to populations throughout history. The most recent one, to date, has been the COVID-19 pandemic, caused by SARS-CoV-2, a member of the family Coronaviridae, that is mainly characterized by severe acute respiratory syndrome. This virus appeared in China in December 2019 and rapidly spread worldwide, creating a public health emergency around the world in 6 months.

Since SARS-CoV2 is a novel pathogen, no standardized treatment is currently available. One proposed agent is chloroquine (CQ), classically known as an antimalarial and immunomodulatory agent. Preclinical evidence suggests that clinical research on CQ in COVID-19 patients is justified (1). In a previous SARS-CoV epidemic, it was proposed that CQ could be considered as a treatment (2, 3). During the first months of the COVID pandemic, a letter-to-the-editor claimed that CQ has shown efficency and safety in an ongoing multicenter study in China for pneumonia caused by SARS-CoV-2, and it was recommended to be included in treatment regimens for COVID-19 pneumonia (4). Therefore, CQ and Hydroxychloroquine (HCQ) have been considered as potential treatments for COVID-19.

Whether systematic reviews of preclinical studies can accurately predict clinical outcomes is controversial. However, preclinical research can provide useful information about the biological plausibility of human drug trials (5). Its special settings that enable direct study of the mechanisms of disease as well as drug pharmacodynamics and pharmacokinetics can aid clinical decision-making (6).

In this systematic review, we aimed to comprehensively synthesize in vitro, animal, and clinical evidence background for the effectiveness and safety of CQ, including its sulfate and phosphate salts, and Hydroxychloroquine for treating patients with COVID-19.

Methods

Protocol and Registration

This systematic review was conducted under emergency conditions of the global coronavirus pandemic. The protocol was developed by a team of clinical epidemiologists (H.R.B. and Y.M.), physicians (H.R.B., MAK, and F.B.), and a librarian (R.V.A.).

Eligibility Criteria

Human controlled studies (including interventional and observational studies), animal studies, and in vitro studies evaluating the effect of CQ, Hydroxychloroquine, or other quinine derivatives on coronavirus infections, including SARS, MERS, and COVID-19, up to June 30, 2020 were included. No limitation was used based on language, publication status, or length of follow-up.

Information Sources

The Cochrane Library, Google Scholar, PubMed (via Medline), Embase, Scopus, and Web of Science, MedRxiv; and clinical trial registries, including clinicaltrials.gov, ChiCTR (Chinese Clinical Trial Registry), IRCT (Iranian Registry of Clinical Trials), and the EU Clinical Trials Register.

Search

The search strategy was developed based on study questions and relevant key words by a medical librarian (R.V.A.) and a physician (F.B.) with systematic review experience for all information sources. An update search was done on July, 30, 2020 for further human studies.

Study Selection

All retrieved records were comprehensively screened based on title by 2 authors independently (F.B. and M.A.K.). Relevant studies were imported into a citation manager (Endnote X7) for screening the abstract after removal of duplicated sources. The abstracts matching the eligibility criteria were selected and categorized into groups based on study type and participants by one reviewer (M.A.K. or F.B.) and the full-texts of the studies were retrieved. We contacted the authors when we could not access the full-texts. The full-texts of the in vitro studies as well as the animal models were reviewed by a virologist (B.S.). The full-texts of clinical studies were evaluated for eligibility by 2 physicians (F.B. and MAK). The references of included articles were hand-searched for further relevant studies.

Data Collection Process

To ensure uniform and comprehensive data extraction among different data extractors, the reviewers developed Microsoft Access forms and tables, including information recommended in the Cochrane Handbook of Systematic Reviews of Interventions (7). These items included the name of the first author, publication year, region, descriptions of study design, participants, interventions, comparisons, outcomes and results, as the sources of funding and key conclusions by the original study authors. Data were extracted by the same review authors who screened the article full-texts.

Risk of Bias in Individual Studies

Risk of bias within the clinical studies was assessed using the Cochrane risk of bias tool, which evaluates studies in 5 domains and rates the study for each domain of bias as having low, unclear, or high risk of bias (8). The ROBINS tool was used to assess risk of bias within nonrandomized studies. The SYRCLE’s tool was used to assess the risk of bias in animal studies (9). OHAT risk-of-bias tool was employed for in vitro studies (10, 11). The risk of bias for each study was assessed by 2 reviewers independently (F.B., B.S., Y.M.) and in case an agreement could not be reached between the first 2 reviewers, a third reviewer would intervene (H.R.B).
Summary Measures and Synthesis of Results

Relative risk and relative risk reduction were used to summarize data for dichotomous outcomes, and mean difference was used for continuous variables. Because of the significant variation in study methodology and outcome measurements, a meta-analysis was not possible for most of the outcomes. Qualitative synthesis was done using the GRADE approach per study outcome. We followed the SWIM guidelines for reporting synthesis without meta-analysis (12). Viral clearance was summarized as the odds ratio of the proportion of patients who tested negative on PCR testing within 10 days of medication use.

Results

Study Selection

A total of 24,752 studies were retrieved by searching the mentioned databases, that were screened by title. Of these, 15,435 abstracts were screened and 115 were selected for full-text review. The eligible studies were categorized at this stage based on their subject (in vitro, animal, and human studies) and were assigned to expert authors for full-text review and final inclusion. Seven human studies were excluded based on full-text, as they were reviews or perspective articles.

The update search retrieved 1628 studies that were screened by title by 1 author. A total of 248 abstracts were screened and 82 full-text articles were screened by 2 authors independently. Finally, we included 18 non-randomized studies and 6 randomized human studies.

The PRISMA flow diagram is presented in Figure 1.

Study Characteristics

Human Studies: We included 6 RCTs and 14 nonrandomized controlled human studies, all of which were conducted among hospitalized patients. None of the studies were placebo-controlled. Also, pregnant and breastfeeding women as well as patients with underlying conditions were excluded. Most studies compared the recommended dose of HCQ daily (ranging from 400mgs/day to 800mgs/day) with drug regimens without HCQ/CQ. Also, 3 studies used a high dose of HCQ, 6 had AZI, and 2 had Lopinavir/ritonavir as part of their control regimen. The follow-up duration varied among the studies and ranged from 7 to 30 days (Tables 1 and 2).
## Table 1. The Risk of Bias within Randomized Controlled Trials

| ID  | First Author     | Random Sequence Generation | Allocation Concealment | Blinding of Participants and Personnel | Blinding of Outcome Assessment | Incomplete Outcome Data | Selective Reporting | Overall  |
|-----|------------------|----------------------------|------------------------|----------------------------------------|-------------------------------|------------------------|--------------------|----------|
| 1   | Chen, Zh†        | L                          | U                      | L                                      | H                             | U                      | U                  | L        |
| 2   | Chen, J‡         | U                          | H                      | H                                      | H                             | U                      | U                  | H        |
| 3   | Tang, W§         | L                          | L                      | U                                      | L                             | L                      | U                  | L        |
| 4   | Borba, MGS†      | L                          | U                      | L                                      | L                             | U                      | L                  | L        |
| 5   | Cavalcanti, AB⁵  | U                          | L                      | H                                      | H                             | H                      | L                  | L        |
| 6   | Huang, M⁶        | U                          | L                      | H                                      | H                             | H                      | L                  | L        |

Guide to the table:  
- **Unclear RoB**: Allocation concealment and blinding procedures were neither explained in the article nor in the protocol. The outcomes reported were completely different from the ones initially planned in the protocol. In the protocol, the researchers planned to evaluate viral clearance and immunologic response. However, they merely reported clinical outcomes in the article.
- **Low RoB**: Unclear description of randomization is given. Antiviral regimens were not the same between groups.
- **High RoB**: Open-label randomized trial. With control group receiving standard care. Reporting of outcomes was complete and dropout frequency was 6 out of 75. Use of intervention varied among participants especially regarding the timing in relation to symptom onset.

1. Randomized controlled trial. The pharmacist distributing the drugs was not blinded, which might have been the source of uncertainty in blinding of participants and personnel.
2. Open-label randomized study with 6-item randomization blocks. Both the patients and the personnel were aware of the randomization group. Selective reporting was unlikely because the protocol was available, and all the predetermined outcomes have been reported. Appropriate use of intention-to-treat analysis makes it unlikely for incomplete reporting to affect study results.
3. Open-label randomized study with 4-item randomization blocks (according to the protocol but not mentioned in the published report). There was a baseline difference between the groups in "days from onset to treatment." Concealment of randomization was done using sealed envelopes. The study protocol was available and the risk of selective reporting was low. However, the published results are preliminary and there is serious risk of data incompleteness.
Outcome measurement was at moderate risk of bias due to the nature of nonblinded and observational nature of the study.

### Table 2. The Risk of Bias within Non-Randomized Controlled Human Studies

| No | First Author          | Bias due to Confounding | Selection Bias | Classification Bias | Deviation from Exposure | Missing Data | Measurement of Outcomes | Selective Reporting | Overall |
|----|-----------------------|--------------------------|----------------|---------------------|-------------------------|--------------|-------------------------|-------------------|---------|
| 1  | Mattheau Mahiéva      | L                        | L              | L                   | M                       | L            | M                       | NI                | M       |
| 2  | Gautret, Philippe     | M                        | M              | M                   | M                       | M            | M                       | NI                | S       |
| 3  | Singh, Sh             | M                        | M              | L                   | L                       | L            | M                       | NI                | S       |
| 4  | Sbidian               | M                        | M              | M                   | L                       | L            | L                       | NI                | S       |
| 5  | Rosenberg             | M                        | L              | L                   | M                       | L            | L                       | M                 | M       |
| 6  | Mehra, MR             | M                        | M              | L                   | S                       | M            | S                       | NI                | S       |
| 7  | Mallat, I             | L                        | L              | S                   | L                       | M            | L                       | NI                | S       |
| 8  | Magagnoli             | L                        | S              | M                   | L                       | M            | L                       | S                 | C       |
| 9  | Lagier, JC            | L                        | S              | S                   | M                       | L            | L                       | L                 | L       |
| 10 | Geleris, J            | M                        | M              | L                   | S                       | M            | M                       | NI                | M       |
| 11 | Yu, B                 | M                        | M              | M                   | M                       | M            | M                       | NI                | S       |
| 12 | Arshad, S             | M                        | L              | L                   | M                       | L            | M                       | NI                | M       |
| 13 | IP, A                 | M                        | M              | L                   | M                       | L            | L                       | M                 | M       |
| 14 | Mazzanti, L           | L                        | L              | L                   | L                       | L            | L                       | M                 | M       |

Guide to the table: L: Low Risk; NI: No Information; M: Moderate Risk; S: Serious Risk; C: Critical Risk

1. Observational study with well-matched between-group baseline characteristics, and the same dosage of chloroquine for all patients. Inconsistency in measurement and recording of the outcomes is suspected.
2. Children who usually have milder course of disease were not included to the treatment group, while they were included in the comparison group. No placebo was used in comparison group. Participants and personnel were not blinded. There was a high dropout rate (6/26) in the treatment group with reasons potentially relevant to the side effects of hydroxychloroquine, including admission to ICU and treatment cessation. An intention-to-treat analysis should have been used.
3. Retrospective cohort analysis of hospital data. Patient selection based on international criteria. Confounding variables addressed by propensity scores in analysis. No information was given on how the exposure use was confirmed. No information was given on how outcomes were assessed. The study protocol was not available to assess the selective reporting. No information was given on missing data.
4. Retrospective study of hospital data on PCR confirmed COVID-19 patients. Augmented inverse probability of treatment weighted (AIPWT) estimates of the average treatment effect (ATE) were used to account for confounding. Data were extracted using artificial intelligence from data systems and manually from medical text reports. Exposures measured according to hospital-registered prescriptions only.
5. Retrospective multicenter cohort. Random sample of patients admitted to 25 hospitals. The exposure dosage and regimens differed across the study sample. A low proportion of patients used HCQ alone. There was inadequate description of how outcome measurement and data extraction were done and there is a high risk of bias due to the variability in exposures and outcome measurements across hospitals.
6. Multinational registry analysis (retrospective observational) on patients with PCR-confirmed COVID-19. Confounding was adjusted for in statistical analysis. No protocol was available; therefore, risk of bias due to selective reporting cannot be estimated. Outcome assessment is suspected to differ significantly across the study centers and due to the observational nature of the study.
7. Retrospective observational study on patient data from 1 hospital. The study methodology was poorly reported. All patients had PCR-confirmed COVID-19. There was significant difference in the frequency of comorbidities between HCQ and control groups, and consequently, a serious risk of bias due to confounding. No information was given on missing data. No study protocol was available to confidently assess selective reporting.
8. Retrospective observational study in 1 veterans’ hospital. All patients had PCR-confirmed COVID-19. Propensity score analysis was used to address confounding. Exposure was defined based on the information from hospital registry of drug dispensing for each patient. No study protocol was available to assess selective reporting. Outcome assessment may cause moderate risk of bias due to the observational nature of the study.
9. Retrospective cohort study. All patients had PCR and culture-confirmed COVID-19. Cardiovascular disease was more common among the control group. The treatment was initiated at an earlier stage of the infection in this study. It is not clear how exposure to the treatments was assessed. No study protocol was available to assess the risk of selective reporting.
10. Retrospective observational study at a quaternary, acute care hospital. Patients had PCR confirmed COVID-19. Confounding was adjusted using propensity score matching analysis. The exposure was evaluated by patient exposure to the drug before or during the admission and thus may vary across participants. No study protocol was available and risk of selective reporting could not be assessed.
11. Retrospective observational study on critically-ill (selection bias) inpatients with CT and PCR-confirmed COVID-19. There was no significant baseline difference in confounding variables between groups. Patient classification (based on drug exposure) may have been subject to error because mere prescription may not show drug use by the patient. No information is given on how the outcome measurements were standardized.
12. A multicenter retrospective observational study on inpatients with PCR-confirmed COVID-19. Treatment regimen were uniform across hospitals. There was moderate risk of bias due to confounding because of the nonrandomized nature of the study and that HCQ was used among patients with more severe disease. This may underestimate the effects of chloroquine. This confounding was partially adjusted for statistically.
13. Retrospective multicenter cohort based on HER data. The study design made it susceptible to bias due to confounding and misclassification. Drug administration was well documented. There was moderate risk of bias due to missing outcome data.
14. Initial results of a prospective observational study with an available protocol. Patients had PCR-confirmed COVID-19. Confounding variables have been well adjusted for. Although the study was observational, enough documentation was performed for the degree of exposure to drugs. Outcome measurement was at moderate risk of bias due to the nature of nonblinded and observational nature of the study.

http://mjiri.iums.ac.ir
Med J Islam Repub Iran. 2020 (17 Dec); 34.171.
Chloroquine and Hydroxychloroquine for COVID-19

Animal Studies: One of the animal studies used SARS-CoV-1 in BALB/c female mice and tested the efficiency of Amodiaquine and CQ, with a dose response design detecting the virus replication in lung homogenates. The other 2 animal studies used HCoV-OC43 virus as the model. One of these 2 studies aimed at identifying the effect of CQ-sulphate in adult C57BL/6 mice followed by studying the protective effect of the drug transferred to litters by placenta or milk of the drug treated mothers. The other study optimized the detection of a luciferase labelled virus in adult BALB/c mice but used the drug CQ as a control to block the virus replication and control the background luciferase detection in treated mice. The study characteristics of the 3 animal studies are summarized in Table 3 in Appendix.

Interestingly, 2 of the animal studies included in vitro examinations as part of their design, which were added to the in vitro studies.

Risk of Bias within Studies
Among the 6 randomized human studies included to the systematic review, the risk of bias due to random sequence generation was unclear among 2 studies. Allocation concealment introduced a high risk of bias in 1 study and was unclear in 2 other studies. Only 1 study was blinded. Two studies were at high risk of bias due to incomplete outcome data, and 1 study was at high risk of bias due to selective reporting. The details are presented in Table 4.

Among the 14 nonrandomized human studies, 7 were at moderate overall risk of bias, 5 were at serious risk, and 2 had a critical risk of bias. The details are presented in Table 5.

Table 3. The Risk of Bias within Animal Studies

| First Author | Randomization | Allocation concealment | Experimental conditions | Exposure characteristics | Reliability of outcome assessment methods | Blinding of outcome assessment | Incomplete outcome data | Selective Reporting |
|--------------|---------------|------------------------|-------------------------|------------------------|------------------------------------------|-------------------------------|----------------------|-------------------|
| Dale L Barnard | 5             | 5                      | 1                       | 3                      | 1                                        | 1                             | 4                    | 3                 |
| Stud 2006     |               |                        |                         |                        |                                          |                               |                      |                   |
| Els Keyaerts  | 2             | 3                      | 2                       | 3                      | 1                                        | 2                             | 3                    | 3                 |
| 2009          |               |                        |                         |                        |                                          |                               |                      |                   |
| Junwei Niu    | 2             | 2                      | 2                       | 1                      | 1                                        | 1                             | 4                    | 5                 |
| 2020          |               |                        |                         |                        |                                          |                               |                      |                   |

Scoring system:
- Definitely High = 1
- Probably High = 2
- Probably Low = 3
- Definitely Low = 4
- Unclear = 5

1. The reporting of the outcome and the statistical methods were appropriate.
2. The presentation on the design of the study has some mistakes and the outcome based on the published design is suboptimal.
3. The number of animals used in the experiment was not clear.

Table 4. Virological Response

| Outcome Description | Study | Study design | HCQ | Control | Effect Estimates | p   |
|---------------------|-------|--------------|-----|---------|------------------|-----|
| Viral clearance after 14 days | Proportion of PCR negative on day 14 | Randomized Clinical study | 10/10 | 11/12 | - | - |
| Chen, J             | Proportion of PCR negative on day 7 | RCT | 13/14 | 2/16 | 91.00 (7.34–112.94) | 0.004 |
| Viral clearance After 6-10 days | Proportion of PCR negative on day 6 | Non-randomized trial | 8/16 | 14/16 | 0.142 (0.024–0.844) | 0.03 |
| Gautret, P          | Proportion of PCR negative on day 10 | Randomized Clinical study | 9/10 | 9/10 | 1.00 (0.053–18.57) | 0.99 |
| Mingxing Huang     | Proportion of PCR negative on day 6 | Randomized trial | 34/75 | 41/75 | 0.687 (0.36–1.30) | 0.25 |
| Tang, W            | Proportion of PCR negative after 10 days | Retrospective cohort | 643/3119 | 151/618 | 0.803 (0.655–0.983) | 0.03 |

Risk of bias was also assessed in animal studies, and they were found to be generally reliable (Table 6).

Synthesis of Results

Human Studies: Because of the heterogeneity in the type of included studies, different methods of outcomes assessment, and the statistical methods for summarizing the results, we could not combine the results in a meta-analysis. Therefore, we synthesized the results qualitatively.

Clinical Response: One study showed a reduced mean of days of having fever for patients in the HCQ group compared to the control (2.2 vs 32) and another study showed fewer number of days with fever for the HCQ group compared to the control group. Taking HCQ was also associated with shortened duration of cough in 1 study (an average of 2 vs 3.1 days). In 1 study, administering HCQ was related to a higher rate of clinical improvement within a course of 28 days, whereas in 2 other studies, HCQ treatment was associated with a higher rate of progression to severe illness.

Adverse Events: The most notable adverse events were GI events, death due to unclear cause, and cardiac adverse events, all of which were more prevalent among the HCQ groups compared to controls (SOC). One study that considered the incidence of “any” adverse event showed a higher incidence among the HCQ group compared to that of the control group. The incidence of other symptoms, such as headache, rashes, nausea, and weakness, were low in both groups, without a significant difference between the HCQ and the control groups.
Tables 4 to 6 present the synthesis of the effect estimates per outcome and Table 7 is the summary of findings in GRADE format.

Table 5. Clinical improvement

| Outcome                           | Study          | Hydroxychloroquine | Control | Effect Estimate (Odds Ratio) Or Mean Difference (SD) with Standardized Mean Difference 95 % CI | p      |
|----------------------------------|----------------|--------------------|---------|-------------------------------------------------------------------------------------------------|--------|
| Fever                            | Chen, Zh       | Mean days (SD)     | 2.7 (0.4) | 3.2 (1.3)                                                                                       | 1.00 (0.51-1.48) | 0.0001 |
|                                  | Chen, J        | Median (range)     | 1 (0-2)  | 1 (0-3)                                                                                         | 0.00 (-0.50-0.50) | 0.98   |
| Cough                            | Chen, Zh       | Mean Days (SD)     | 2 (0.2)  | 3.1 (1.5)                                                                                       | 1.1 (0.55-1.64) | 0.002  |
| Clinical improvement             | Tang,          | The improvement rate of clinical symptoms within 28-day       | 47/70   | 48/80                                                                                           | 1.36 (0.69-2.66) | 0.36   |
| Discharge home or to a rehab center | Sbidian  | Number of patients | 351/623 | 1507/3792                                                                                      | 1.95 (1.64-2.32) | 0.001  |
|                                  | Magagnoli      | Number of patients | 70/97   | 140/158                                                                                         | 2.92 (1.77-4.81) | 0.001  |
|                                  | Mingxing Huang | Proportion of hospital discharge on day 14                    | 10/10   | 6/12                                                                                           | -       | -      |
|                                  | Mahevas        | Proportion of patients discharged by day 21                   | 67/84   | 71/89                                                                                          | 1.0 (0.9-1.2) | -      |
| Clinical progression to severe illness | Chen, Zh   | Rate of Progression to severe illness                         | 4/31    | 3/31                                                                                           | -       | -      |
| Mean length of hospital stay     | Cavalcanti     | Duration of hospital stay                                     | 9.6(5.6) | 9.5(7.2)                                                                                       | -0.1 (-1.58-1.38) | 0.89   |
| Radiological response            | Mingxing Huang | Proportion of CT-scan improvement (day 10)                    | 7/10    | 5/12                                                                                           | 3.26 (0.55-19.25) | 0.19   |
|                                  |                 | Proportion of CT-scan improvement (day 14)                    | 10/10   | 9/12                                                                                           | -       | -      |

Table 6. Adverse events

| Outcome category                  | Study          | Hydroxychloroquine | Control | Effect Estimate (Odds Ratio) Or Mean Difference (SD) with Standardized Mean Difference 95 % CI | p      |
|----------------------------------|----------------|--------------------|---------|-------------------------------------------------------------------------------------------------|--------|
| Fatal outcomes                   | Sbidian        | 111/623            | 865/3792 | 0.781 (0.630-0.968)                                                                 | 0.02   |
| Death (any cause)                | Gautret, P     | 1/26               | 0/16    | -                                                                                               | -      |
|                                  | Rosenberg      | 54/271             | 28/221  | 1.715 (1.044-2.816)                                                                             | 0.03   |
|                                  | Singh          | 104/910            | 109/910 | 0.948 (0.71–1.26)                                                                               | 0.14   |
|                                  | Lagier         | 2/101              | 4/162   | 0.798 (0.14–4.43)                                                                               | 0.79   |
|                                  | Magagnoli      | 27/97              | 18/158  | 3.00 (1.54–5.81)                                                                                | 0.001  |
|                                  | Yu, B          | 9/48               | 238/502 | 0.25 (0.12–0.53)                                                                                | 0.001  |
|                                  | Cavalcanti, AB | 7/159              | 6/173   | 1.26 (0.42–3.89)                                                                                | 0.6    |
| Cardiac arrest outcomes          | Andrew, Ip     | 110/440            | 119/598 | 1.33 (1.00–1.79)                                                                                | 0.050  |
| QT prolongation                  | Mahévas, M     | 8/84               | 8/89    | 1.2 (0.5-3)                                                                                     | -      |
| Cardiac adverse outcomes         | Mahévas, M     | 262/811            | 84/565  | 2.73 (2.07–3.59)                                                                                | 0.000  |
| Need for mechanical ventilation  | Mahévas, M     | 3/84               | 4/97    | 0.86 (0.18–3.96)                                                                                | 0.84   |
| ICU transfer                     | Borba,         | 16/41              | 6/41    | 3.73 (1.28-10.57)                                                                               | 0.01   |
| Severity-related outcomes        | Sbidian        | 37/271             | 15/221  | 2.19 (1.69-4.11)                                                                                | 0.01   |
| Need for mechanical ventilation  | Rosenberg      | 44/271             | 23/221  | 1.668 (0.972-2.860)                                                                             | 0.06   |
| ICU transfer                     | Rosenberg      | 39/271             | 13/221  | 2.689 (1.397–5.17)                                                                              | 0.003  |
| Cardiac arrest outcomes          | Nicholas J Mercuro | 3/37            | 7/53    | 0.579 (0.14–2.40)                                                                               | 0.45   |
| QT prolongation                  | Mahévas, M     | 8/84               | 6/58    | 3.73 (1.28-10.57)                                                                               | 0.01   |
| Cardiac adverse outcomes         | Mahévas, M     | 49/10              | 57/910  | 0.796 (0.53-1.18)                                                                               | 0.26   |
| Need for mechanical ventilation  | Rosenberg      | 12/159             | 12/173  | 1.09 (0.47-2.51)                                                                                | 0.83   |
| ICU transfer                     | Rosenberg      | 55/271             | 27/221  | 2.19 (1.16–4.11)                                                                                | 0.01   |
| Severity-related outcomes        | Shbidian       | 206/623            | 739/3792| 2.04 (1.69-2.45)                                                                                | 0.50   |
| Need for mechanical ventilation  | Mahévas, M     | 24/84              | 23/95   | 1.25 (0.64-2.44)                                                                                | -      |

Animal Studies: Two animal studies showed the effectiveness of CQ in mice models using a wild type HCoV-OC43 and another recombinant rOC43-nS2DelRluc from
Chloroquine and Hydroxychloroquine for COVID-19

Table 6. Ctd.

| Outcome category          | Outcome          | Study              | Hydroxychloroquine | Control | Effect Estimate (Odds Ratio) Or Mean Difference (SD) with Standardized Mean Difference 95% CI | p     |
|---------------------------|------------------|--------------------|--------------------|---------|------------------------------------------------------------------------------------------------|-------|
| Gastrointestinal adverse outcomes | Nausea           | Gautret, P         | 1/26               | 0/16    | -                                                                                                    |       |
|                           | Diarrhea         | Rosenberg          | 22/271             | 16/221  | 1.13 (0.58–2.21)                                                                                     | 0.71  |
| Other adverse outcomes    | Any Adverse effect | Tang               | 21/70              | 7/80    | 4.49 (1.75–11.31)                                                                                   | 0.001 |
|                           | Rash             | Chen, Zh           | 1/31               | 0/31    | -                                                                                                    |       |
|                           | Hypoglycemia     | Rosenberg          | 9/271              | 6/221   | 1.230 (0.44–3.51)                                                                                   | 0.38  |
|                           | Paresthesia      | Tang               | 9/80               | 2/80    | 4.943 (1.03–23.65)                                                                                   | 0.04  |
|                           | Paresthesia      | Chen, J            | 1/13               | 0/14    | -                                                                                                    |       |
|                           | Weakness         |                    |                    |         |                                                                                                     |       |

Table 7. GRADE summary of findings table

| Outcomes                              | No of participants (studies) | Certainty of the evidence (GRADE) | Comments                                                                 |
|---------------------------------------|-----------------------------|-----------------------------------|-------------------------------------------------------------------------|
| Virological Response                  | 232 (9 RCTs)                | VERY LOW abcd                      | The evidence is very uncertain about the effect of hydroxychloroquine on the rate of viral clearance after one week of treatment. There are two RCTs, two non-randomized trials, and two retrospective cohort studies with significantly inconsistent results. |
| evaluated with: negative throat swabs on day 6-7 post-enrollment |                             |                                   |                                                                         |
| Symptom Improvement                   | 286 (4 RCTs)                | VERY LOW abcde                     | The evidence is very uncertain about the effect of hydroxychloroquine on symptom improvement. The study results are inconsistent and inconclusive. |
| Radiological Progression              | 89 (2 RCTs)                 | VERY LOW abcde                     | Hydroxychloroquine may have little positive to no effect on radiological progression but the evidence is very uncertain and more research is needed. |
| ICU Admission                         | 5433 (5 observational studies) | VERY LOW abcde                     | The evidence is very uncertain whether chloroquine/hydroxychloroquine could affect the rate of ICU admission. |
| Cardiac Adverse Events                | 501 (5 RCTs)                | VERY LOW abcde                     | Hydroxychloroquine may significantly increase the rate of adverse events especially QT prolongation and cardiovascular death but the evidence is very uncertain. Current available evidence is very uncertain whether and in what direction chloroquine/hydroxychloroquine could affect mortality due to COVID-19. The evidence is inconclusive and inconsistent. |
| Death                                 | 10668 (10 observational studies) | VERY LOW abcde                     |                                                                         |
| Gastrointestinal Adverse Effects      | 693 (6 observational studies) | VERY LOW abcde                     | The evidence is very uncertain and variable regarding the effect of HCQ on the rate of gastrointestinal adverse events (nausea/vomiting/diarrhea) in patients with COVID19. |
| follow up: range 5 days to 30 days    |                             |                                   |                                                                         |

Explanations
a. Three studies reported this outcome. None was blinded and one was not randomized.
b. There is significant heterogeneity in trial results. This might be due to differences in outcome measurements and also study populations.
c. There is special concern for publication bias due to the recent emergence of the disease and the timing of this review. Trials that are not published yet may show different results.
d. None of the studies were placebo-controlled and the standard-of-care which was the control intervention in all of the studies, differed within and across studies. The methods of outcome measurement also differed across studies. Another concern is about time from symptom-onset to treatment initiation which is different and not described in adequate detail.
e. Total number of patients in the control group=110. confidence intervals
f. Total number of patients in the control group for this outcome =111

which the ns-2 gene was replaced with a reporter gene. In both models, intracerebral inoculation of the virus was treated with CQ and improved the survival of the infected mice compared with the animals in the control group. The models were not similar: one study examined survival in suckling mice but the other assessed survival of adult mice. Also, the viruses were not identical in the 2 models. CQ in another mice model did not block infection by SARS-CoV.
In vitro Studies: Recent studies of COVID-19 showed promising results with CQ and HCQ in Vero cell models reported in 3 studies published in 2020 (13). Also, all studies, except 1 which used human primary cells, reported the efficiency of the drug in cell models. Although the selectivity index of the studies varied, they generally show that the drug is safe. Additionally, the amount of virus used to assess the blocking effect of the drugs on virus replication varied between studies, and higher viral inoculates correlated with a higher dose of drug needed to block the virus infection. All in vitro studies supported the antiviral effect of CQ and HCQ in human coronaviruses, including SARS, MERS, and COVID-19. Factors that may limit the applicability of these results include the use of established cell lines, mostly Vero cells, and only 1 or 2 strains of each virus.

Discussion
Summary of the Evidence
Figure 2 presents a concept map of the interaction between HCQ and different mechanisms involved in pathogenesis of COVID-19.

Antiviral Effects of CQ/HCQ
HCQ has been proposed to have antiviral activity and has been used against many viral infections, including HIV (14-26), influenza (27-32), chikungunya virus (33-39), and many other viruses (36, 37, 40-44), albeit with variable levels of clinical effectiveness. Our systematic review reveals a consistently positive antiviral effect for HCQ in vitro and animal studies; however, these effects varied significantly in human studies. Most of human studies used the drug at later stages of the illness compared with animal studies, which may be the reason for the inconsistency in findings across human and animal studies. Moreover, previous studies have shown that animal studies cannot accurately predict clinical outcomes in humans (6). This concept has been reproduced in our systematic review. Thus, based on these limited findings, we cannot conclude whether HCQ is a safe and effective antiviral agent for the treatment of COVID19.

Immunomodulatory Effects of CQ/HCQ
COVID-19 is asymptomatic to mildly symptomatic in most patients. However, in a smaller number of patients with more severe disease, severe inflammatory response, cytokine storm, and macrophage activation syndrome, it may lead to ARDS and multiorgan failure, which may potentially lead to death (45, 46). Cytokine release syndrome (CRS) is associated with higher adverse outcomes among patients with COVID19 (47-49) and may indirectly decrease viral clearance via decreasing T-cell number and function (50, 51). Immune modulating drugs such as steroids have been shown to improve outcomes (52, 53). Hydroxychloroquine is one of these potential agents that modulates immune reaction by decreasing pro-inflammatory cytokine release and decreasing the risk of macrophage activation syndrome in patients with systemic lupus erythematos without significant immunosuppression (54-60). In our systematic review, 2 included clinical studies evaluated immunologic markers in COVID-19 patients under treatment with HCQ and found significant reduction in inflammatory cytokines in these patients, although the overall quality of these studies was very low (61, 62). Three other studies compared cytokines (IL-6 and TNF-alpha) between HCQ and SOC patients and did not find any significant difference, but our certainty in these results is also very low (63-67).
Chloroquine and Hydroxychloroquine for COVID-19

**Anticoagulant Effects of CQ/HCQ**

In light of the evidence suggesting hypercoagulable state and its possible role in the pathogenesis of severe COVID-19, this particular pathway may be an important target for treatment (68, 69). Anticoagulants have been shown to decrease mortality in COVID-19 patients (70). In 1 study, patients with COVID-19-associated pneumonia had a markedly higher level of D-dimer and higher platelet count than patients with non-COVID-19-associated pneumonia (71). A multicenter study that included 150 patients with COVID-associated ARDS found that >95% of the patients had an elevated D-dimer level and 50 of 57 of the tested patients were positive for lupus anticoagulant antibodies (72). Nevertheless, these results are inconsistent with another study which found no association between antiphospholipid antibodies and COVID-19 prothrombotic state (73). In another cohort of hospitalized patients with COVID-19, the hypercoagulable state in these patients is more consistent with a severe inflammatory state than DIC (74). HCQ has been shown to decrease thrombotic events in patients with antiphospholipid syndrome by interfering with assembly of endosomal NADPH oxidase-2, which is involved in thrombotic events and affects inflammatory state in antiphospholipid syndrome (58, 75).

**Drug and Disease-related Adverse Outcomes**

Cardiovascular events, including acute cardiac injury, shock, and arrhythmias, were present in 7.2%, 8.7%, and 16.7% of patients with COVID-19, according to a cohort study of hospitalized patients (76). These patients are at an increased risk of in-hospital events, including ICU admission and death (77-79). In a recent study, a combination of azithromycin and HCQ was associated with an increase in the QTc interval to more than 500 milli seconds in 11% of the 84 patients with COVID-19. This effect was significantly more common among patients with renal failure (80). In a retrospective cohort study on multinational databases collectively including millions of patients, it was found that new users of HCQ alone were not at a significantly increased risk of adverse effects; nonetheless, its combination with azithromycin was associated with an increased risk of death associated with cardiovascular events among patients with rheumatoid arthritis (81). These findings present indirect evidence on cardiovascular outcomes among chloroquine users. Moreover, the doses and disease-drug interaction and effect on the heart may differ considerably in COVID-19. Therefore, clinicians should be especially cautious about the cardiac adverse effects of chloroquine, especially its combination with azithromycin or Oseltamivir, and their possible synergistic activity with COVID-19 effects on the heart (82).

Toxicity with quinine agents, including chloroquine and HCQ, has also been reported to cause pulmonary side effects, including an ARDS-like syndrome (83-85), bronchiolitis obliterans organizing pneumonia (BOOP) (86), and pulmonary edema (87-89). A retrospective study of Wuhan patients with COVID-19 reported nervous system involvement among 78 of 214 (36.4%) patients as a part of the clinical presentation in COVID-19. It involves both the peripheral and the central nervous system, with symptoms ranging from dizziness and headache to impairments in taste and smell and even to stroke, seizures, and encephalitis. The proposed pathophysiologic mechanism is a direct brain invasion as in SARS and MERS (90). Seizure has also been reported with chloroquine use, although this was not confirmed in trials as an adverse effect; clinicians should be cautious when prescribing this drug in patients with epilepsy (91).

**Relevance to Researchers and Care Providers**

The available studies have significant methodological limitations, many of which are due to the difficulties associated with the special circumstances during a pandemic. Whether chloroquine can be clinically effective remains a question. One potential reason for the inconsistency between preclinical and clinical studies can be the interval between infection and treatment initiation, which may affect the potential antiviral effects of chloroquine. We recommend researchers to design trials of chloroquine at earlier phases of the infection and among outpatients. We also recommend systematic and globally homogenous monitoring and reporting of the side effects and clinical outcomes.

**Relevance to Care Providers**

Based on current evidence, we recommend clinicians against the routine use of chloroquine/HCQ in patients with COVID-19, as the drug has not shown clinical efficacy and may be associated with life-threatening side effects, especially when prescribed with other routinely prescribed medications, such as azithromycin and Oseltamivir. Thus, special care must be taken for patients at risk for QT prolongation.

**Limitations of the Evidence and the Review**

The quality of the included studies was low to very low. No placebo-controlled studies were available and only one of the studies was blinded. There was significant variation in outcomes and methodology across the studies, thus, a meta-analysis could not be conducted. All of the studies included hospitalized patients only and the results cannot be generalized to all patients with COVID-19.

**Novelty**

We present a holistic viewpoint by synthesizing the in vitro, animal, and human (observational and interventional) evidence on the benefits and risks associated with the use of chloroquine/HCQ in patients with COVID-19 with a rigorous methodology. A few systematic reviews have already been published that focused on the same review question. However, our study is unique in presenting a holistic approach combining the results from preclinical studies with nonrandomized and randomized human studies and presenting a basic science based clinically oriented viewpoint.

**Conclusion**

There is insufficient evidence to draw conclusions on the efficacy and safety of chloroquine and Hydroxychloroquine based on current evidence. Available studies have significant methodological limitations and the results are
inconsistent.

The authors declare that they have no competing interests.

References

1. Cortegiani A, Ingolliga G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020; 3(10):279-283

2. Savarino A, Boelaert JR, Cassone A, Majori G, Gauda R. Effects of chloroquine on viral infections: An old drug against today’s diseases? Lancet Infect Dis. 2003;3(11):722-7.

3. Cinat JR, Michaelis M, Hoever G, Preiser W, Doerr HW. Development of antiviral therapy for severe acute respiratory syndrome. Antiviral Res. 2005;66(2-3):81-97.

4. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;vol(no).pp.

5. Cox LA. Modernizing the Bradford Hill criteria for assessing causal relationships in observational data. Crit Rev Toxicol. 2018;48(8):682-712.

6. Pound P, Ritskes-Hoitinga M. Can prospective systematic reviews of animal studies improve clinical translation? J Transl Med. 2020;18(1):15-44

7. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions: John Wiley & Sons; 2019.

8. Higgins JP, Altman DG, Gøtzsche PC, Jønsson B, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

9. Hooijmans CR, Rovers MM, De Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE’s risk of bias tool for animal studies. BMC Med Res Methodol. 2014;14(1):43.

10. Morgan RL, Thayer KA, Santesso N, Holloway AC, Blain R, Eftim SE, et al. Evaluation of the risk of bias in non-randomized studies of interventions (ROBINS-I) and the ‘target experiment’ concept in studies of exposures: rationale and preliminary instrument development. Environ Int. 2019;120:382-7.

11. Pega F, Norris SL, Backes C, Bera LA, Descatha A, Gagliardi D, et al. RoB-SPEO: A tool for assessing risk of bias in studies estimating the prevalence of exposure to occupational risk factors from the WHO/ILO Joint Estimates of the Work-related Burden of Disease and Injury. Environ Int. 2020;135:105039.

12. Campbell M, McKenzie JE, Sovendr A, Katikireddi SV, Brennan SE, et al. RoB-2: A tool for assessing risk of bias in studies of interventions. BMJ. 2018;362:k2368.

13. Niu J, Shen L, Huang B, Ye F, Zhao L, Wang H, et al. Non-invasive bioluminescence imaging of HCoV-OC43 infection and therapy in the central nervous system of live mice. Antiviral Res. 2020;173:104646.

14. Bhushan P, Aggarwal A, Balyan V. Complete clearance of cutaneous Chikungunya arthritis. An open pilot study. S Afr Med J. 2016;106(6):217-8.

15. Chopra A, Saluja M, Venugopalan A. Effectiveness of chloroquine and inflammatory cytokine response in patients with early persistent musculoskeletal pain and arthritis following chikungunya virus infection. Arthritis Rheumatol. 2014;66(2):319-26.

16. De Lamballerie X, Boisson V, Reyner JC, Enault S, Charrel RN, Flahault A, et al. On chikungunya acute infection and chloroquine treatment. Vector Borne Zoonotic Dis. 2008;8(6):837-9.

17. Dowall SD, Bosworth A, Watson R, Bewley K, Taylor I, Rayner E, et al. Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model. J Gen Virol. 2015;96(Pt 12):3484.

18. Faiz SS, El Zanetti M, Khoury J, Hafid F, Quansah K, Galal A, et al. A randomized controlled open label study of chloroquine in patients with COVID-19 receiving antiretroviral therapy: a randomized controlled trial. J Clin Rheumatol. 2017;23(6):348-51.

19. Al-Farraj H, Al-Musaid M, Al-Ajmi A, Al-Harthy F, Al-Muhairy A, et al. Chloroquine and hydroxychloroquine for COVID-19: A systematic review of randomized controlled trials. J Med Assoc Egypt. 2020;113(6):656-62.

20. Paton N, Aboulhaj J. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy in HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks. HIV Med. 2005;6(1):13-20.

21. Paton NI, Aboulhaj J, Karim F. Hydroxychloroquine, hydroxyurea, and didanosine as economic treatment for HIV-1. Lancet. 2002;359(9281):1667-8.

22. Paton NI, Goodall RL, Dunn DT, Franzen S, Collaco-Moraes Y, Gazzard BG, et al. Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial. JAMA. 2012;308(4):353-61.

23. Piconi S, Parissot S, Rizzardini G, Passerini S, Terzi R, Argenteri B, et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy–treated immunologic nonresponders. Am J Hematol. 2011;86(12):3263-72.

24. Routy JP, Angel JB, Patel M, Kanagaratnam C, Radziioch D, Kena M, et al. Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy. HIV Med. 2015;16(1):48-56.

25. Sperber K, Chiang C, Chen H, Ross W, Chusid E, Gonchar M, et al. Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. Clin. Ther. 1997;19(5):913-23.

26. Sperber K, Louie M, Kraus T, Proner J, Sapira E, Lin S, et al. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin Ther. 1995;17(4):622-36.

27. Sperber K, Louie M, Kraus T, Proner J, Sapira E, Lin S, et al. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin Ther. 1995;17(4):622-36.

28. Sperber K, Louie M, Kraus T, Proner J, Sapira E, Lin S, et al. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin Ther. 1995;17(4):622-36.

29. Vigerust DJ, McCullers JA. Chloroquine is effective against influenza A virus in vitro but not in vivo. Influenza Other Respir Viruses. 2007;1(5-6):189-92.

30. Yan Y, Zou Z, Sun Y, Li X, Xu KF, Wei Y, et al. Anti-malarial drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res. 2013;23(2):300-2.

31. Ooi EE, Chew JSW, Loh JP, Chua RC. In vitro inhibition of human and avian influenza A virus by chloroquine. J Antimicrob Chemother. 2010;65(4):731-4.

32. Chow P, Varga J, de Souza L, Choa S, Poon L, Fang H, et al. Chloroquine phosphate treatment for chronic Chikungunya arthritis. A randomized controlled open label study. J Inf Secur. 2015;104646.

33. Chopra A, Saluja M, Venugopalan A. Effectiveness of chloroquine and inflammatory cytokine response in patients with early persistent musculoskeletal pain and arthritis following chikungunya virus infection. Arthritis Rheumatol. 2014;66(2):319-26.

34. De Lamballerie X, Boisson V, Reyner JC, Enault S, Charrel RN, Flahault A, et al. On chikungunya acute infection and chloroquine treatment. Vector Borne Zoonotic Dis. 2008;8(6):837-9.

35. Al-Farraj H, Al-Musaid M, Al-Ajmi A, Al-Harthy F, Al-Muhairy A, et al. A randomized controlled open label study of chloroquine in patients with COVID-19 receiving antiretroviral therapy: a randomized controlled trial. J Clin Rheumatol. 2017;23(6):348-51.

36. Raivand V, Alias G. Efficacy of combination DMARD therapy vs. chloroquine in patients with rheumatic disease: a 24-week randomized controlled open label study. J Clin Rheumatol. 2017;36(6):1335-40.

37. Sperber K, Louie M, Kraus T, Proner J, Sapira E, Lin S, et al. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin Ther. 1995;17(4):622-36.

38. Ravindran V, Alias G. Efficacy of combination DMARD therapy vs. chloroquine in patients with rheumatic disease: a 24-week randomized controlled open label study. J Clin Rheumatol. 2017;36(6):1335-40.

39. Sperber K, Louie M, Kraus T, Proner J, Sapira E, Lin S, et al. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin Ther. 1995;17(4):622-36.

40. Li C, Zhu X, Ji X, Quanquin N, Deng YQ, Tian M, et al. Chloroquine, hydroxychloroquine, and hydroxyurea as initial therapy in HIV-infected patients receiving antiretroviral therapy: a randomized controlled trial. JAMA. 2012;308(4):353-61.

41. F. Barzkar, et al.
Chloroquine and Hydroxychloroquine for COVID-19

41. Bönisch C, Kempf C, Mueller I, Manning L, Laman M, Davis TME, et al. Chloroquine and Its Derivatives Exacerbate B19V-Associated Anemia by Promoting Viral Replication: e669. PLOS Neg Trop Dis. 2010;4(4):e669.

42. Gressers LT, Bordin AI, McQueen CM, Cohen ND, de Vargas AC. Chloroquine inhibits Rhodococcus equi replication in murine and foal alveolar macrophages by iron-starvation. Vet Microbiol. 2016;188:16-24.

43. Palijster J, Middleton D, Cramer G, Yamada M, Klein R, Hancock TJ, et al. Chloroquine administration does not prevent Nipah virus infection and disease in ferrets. J Virol. 2000;2005:11079-82.

44. Tan YW, Yam WK, Sun, J Chu JH. An evaluation of Chloroquine as a broad-acting antiviral against Hand, Foot and Mouth Disease. Antiviral Res. 2018;149:143-9.

45. Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China. J Clin Immunol. 2020;108393.

46. Moy S, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol. 2020;1.

47. Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China. J. Clin. Immunol. 2020;214.

48. Nidadavolu LS, Walston JD. Underlying Vulnerabilities to the cytokine storm in COVID-19 Outcomes in the Aging Immune System. J Gerontol. 2020;7(10):223-32.

49. Gao YM, Xu G, Wang B, Liu BC. Cytokine storm syndrome in coronavirus disease 2019: A narrative review. J Intern Med. 2020;10(3):1-8.

50. Bhaskar S, Sinha A, Banach M, Mittoo S, Weissert R, Kass JS, et al. Chloroquine and Its Derivatives Exacerbate B19V-Associated Anemia by Promoting Viral Replication: e669. PLOS Neg Trop Dis. 2010;4(4):e669.

51. Meyerowitz EA, Vannier AGL, Friesen MGN, Schoenfeld S, Gelfand M, et al. Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: A prospective open-label randomized controlled study. medRxiv. 2020;2020.04.16.20060558.

52. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. medRxiv. 2020;2020.04.10.20060558.

53. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. MedRxiv. 2020;1.

54. Chen L, Zhang ZY, Fu JG, Feng ZP, Zhang SZ, Han QY, et al. Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study. medRxiv. 2020;1.

55. Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab Syndr. 2020;14(3);241-46.

56. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford, England). 2006;45(6):703-10.

57. Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, et al. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020;18(2):1738-1742.

58. Plantone D, Koudriavtseva T. Current and Future Use of Chloroquine and Hydroxychloroquine in Infections, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. Clin Drug Investig. 2018;38(8):653-71.

59. Yin S, Huang M, Li D, Tang N. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J Thromb Thrombolysis. 2020;13(3):102-9.

60. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delbranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089-98.

61. Previgliati G, Seghezzi M, Moioi V, Sonzogni A, Marozzi R, Cerutti L, et al. the pathogenesis of thromboembolic disease in COVID-19 patients: Could be a catastrophic antiphospholipid syndrome? medRxiv. 2020;1.

62. Dong N, Cai J, Zhou Y, Liu J, Li F. End-stage Heart Failure with Myocardial Injury by 2019-nCoV. J Thromb Haemost. 2020;18(2):1738-1742.

63. Chien W, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. Bmj. 2020;368.

64. Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab Syndr. 2020;14(3);241-46.

65. Chien W, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. Bmj. 2020;368.

66. Vishnu A, Bhat S, Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab Syndr. 2020;14(3);241-46.
Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study). medRxiv. 2020;2020.04.07.20056424.

83. Gordon S, Cordon RA, Mazdzer EJ. Adult respiratory distress syndrome in babesiosis. Chest. 1984;86(4):633-4.

84. Ndiaye N, Petrognani R, Diatta B, Seck M, Theobald X, Adnet P. Chloroquine poisoning with respiratory distress and fatal outcome. Ann Fr Anesth Reanim. 1999;18(6):683-5.

85. Wenstone R, Bell M, Mostafa SM. Fatal adult respiratory distress syndrome after quinine overdose. Lancet. 1989;1(8647):1143-4.

86. Rahman M, Hashmey R, Abuhasna S. Quinine-induced bronchiolitis obliterans and organizing pneumonia. J Anaesthesiol Clin Pharmacol. 2012;28(4):505-7.

87. Everts RJ, Hayhurst MD, Nona BP. Acute pulmonary edema caused by quinine. Pharmacotherapy. 2004;24(9):1221-4.

88. Katsenos S, Psathakis K, Nikolopoulou MI, Constantopoulos SH. Mefloquine-induced eosinophilic pneumonia. Pharmacotherapy. 2007;27(12):1767-71.

89. Mitja K, Izidor K, Music E. Chloroquine-induced drug-hypersensitivity. Pneumologie. 2000;54(9):395-7.

90. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020; 54(9):395-397.

91. Pati S. A systematic review to assess seizure risk with chloroquine therapy in persons with epilepsy. medRxiv. 2020;2020.04.09.20056358.
### Characteristics of Non-Randomized Controlled Human Studies

| Study first author, Country | Design | Setting | Participants | Interventions/Exposure | Comparison | Outcome | Follow-up |
|-----------------------------|--------|---------|--------------|------------------------|------------|---------|----------|
| Mahévas M. France           | Retrospective cohort, Four centers | Inpatient | Hospitalized patients with COVID-19 Aged 18-80 Requirement=2 L/min of oxygen | Hydroxychloroquine 600 mg/day within 48 hours of enrollment (48) | Usual care (97) | – transfer to the ICU within 7 days of inclusion | 7 days |
| Gautret, Philippe France    | open-label non-randomized clinical trial, single center | Inpatient | Hospitalized patients with RT-PCR-confirmed COVID-19 Age >12 years | Hydroxychloroquine sulfate 600mg with and without azithromycin for ten days (20/26) | components of usual care 16/16) | Virological clearance at day-6 post-inclusion | 14 days |
| Mazzanti, A Italy           | ongoing, observational, prospective study | Inpatient | a diagnosis of COVID-19 confirmed by polymerase chain reaction | HCQ 400mg or 600mg (50) | Azithromycin (39), Lopinavir/ritonavir (52) or azithromycin+Lopinavir/ritonavir (9) | – in-hospital mortality (cardiac arrest - abnormal ECG (arrhythmia or prolonged QT interval)) | Not finished yet |
| Rosenberg, E. S US          | Retrospective multi-center cohort | Inpatient | Inpatients with a laboratory-confirmed diagnosis of CoVid19 | Oral HCQ alone (271) or HCQ+ AZI (735). The dosing differed across patients. The majority took HCQ 400 mg once to twice daily. HCQ alone : 600mg on the first day, 400mg daily for the next 9 days (623) | HCQ : 600mg first day, 400mg daily for the next 9 days + AZI :500mg on the first day followed by 250mg daily for the next 4 days (227) OR neither of HCQ or AZI (3792) | - all-cause 28-day mortality - 28-day discharge home | 21 days |
| Sbidian, E France           | Retrospective cohort | Inpatient | adult inpatients with at least one PCR-confirmed SARS-CoV-2 RNA from a nasopharyngeal sample | HCQ (910) Varied dosing | -7,-14, and 30-day mortality - need for mechanical ventilation - incidence of new ventricular events (ie: fibrillation, tachycardia) or sudden cardiac death | 30 days |
| Singh, S US                 | Retrospective cohort | Inpatient | hospitalized adult patients (> 18 years) diagnosed with clinical and laboratory-confirmed COVID-19 | HCQ : 200mg TID for 10 days (38) | Standard of care only (46) | -time to unfavorable outcome; e.g. death, need for ICU admission -time to death -time to hospital discharge to home or an aftercare unit -fever and cough at day 5 -adverse events in the HCQ group | 10 days |
| Paccoud, O France           | Retrospective cohort | Inpatient | All the patients hospitalized with a diagnosis of CoVid-19 via RT-PCR from a nasopharyngeal swab or sputum specimen | HCQ 200mg TID for 10 days (38) | Standard of care only (46) | -time to unfavorable outcome; e.g. death, need for ICU admission -time to death -time to hospital discharge to home or an aftercare unit -fever and cough at day 5 -adverse events in the HCQ group | 10 days |
### Appendix Table 1

| Study first author, Country | Design                      | Setting          | Participants                                                                 | Interventions/Exposure                                                                 | Comparison                  | Outcome                                                                 | Follow-up |
|-----------------------------|-----------------------------|------------------|-------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|-----------------------------|-------------------------------------------------------------------------|-----------|
| Mallat, J UAE                | Retrospective observational study | Inpatient        | Hospitalized adult patients with confirmed SARS-CoV-2 infection (using RT-PCR for a nasopharyngeal swab) | HCQ 400 mg twice for day 1, followed by 400 mgs daily for 10 days (23)                  | No HCQ (11)               | -Time to SARS-CoV-2 negativity test<br>-turning negative on day 14<br>-Time course of inflammatory variables between admission and day seven or hospital discharge<br>-in-hospital mortality<br>-the first occurrence of a non-sustained [at least 6 sec] or Sustained ventricular tachycardia or ventricular fibrillation during hospitalization<br>-rates of progression to mechanical ventilation use and the total and intensive care unit lengths of stay | 14 days   |
| Mehra, MR Six continents     | Retrospective observational cohort study | Inpatient        | All hospitalized patients with a PCR-confirmed COVID-19 infection              | CQ: 765 mg [SD=308] for a mean of 6.6 [SD=2.4] days (1868)<br>HCQ 596 [SD=126] mgs for a mean of 4.2 [SD=1.9] days (3016) | Neither drug (SOC) 81144 | All hospitalized patients with a PCR-confirmed COVID-19 infection<br>-in-hospital mortality<br>-the first occurrence of a non-sustained [at least 6 sec] or Sustained ventricular tachycardia or ventricular fibrillation during hospitalization<br>-rates of progression to mechanical ventilation use and the total and intensive care unit lengths of stay | Not mentioned |
| Geleris J US                 | Retrospective cohort         | Inpatient        | all admitted adults with a positive RT-PCR test for SARS-CoV-2 from analysis of nasopharyngeal or oropharyngeal swab specimens obtained at any point during their hospitalization all individuals >18 years of age with PCR-documented SARS-CoV-2 RNA from a nasopharyngeal sample | HCQ: 600mg twice on day 1, followed by 400 mg daily for 4 additional Days (811)       | SOC (565)                | All individuals >18 years of age with PCR-documented SARS-CoV-2 RNA from a nasopharyngeal sample<br>-in-hospital mortality<br>-the first occurrence of a non-sustained [at least 6 sec] or Sustained ventricular tachycardia or ventricular fibrillation during hospitalization<br>-rates of progression to mechanical ventilation use and the total and intensive care unit lengths of stay | median follow-up of 22.5 days |
| Lagier, JC France            | Retrospective cohort         | Inpatient or day-care | 200 mg of oral HCQ, three times daily for ten days                            | HCQ alone (101)                                                                    | HCP+AZI (3337)<br>AZI alone (137)<br>Neither drug(162) | -death<br>-transfer to ICU<br>-more than 10 days of hospitalization<br>-viral shedding | At least 9 days |
| Magagnoli US                 | Retrospective cohort         | Inpatient        | patients with laboratory confirmed SARS-CoV-2 infection                      | HCQ (97)                                                                            | No HCQ (158)             | -the result of the hospitalization (discharge or death)<br>-the result of hospitalization among patients requiring ventilation | Not mentioned |
| Ip, A                       | Retrospective multi-center cohort | Inpatient        | Positive SARS-CoV-2 diagnosis by RT-PCR and not pregnant                    | HCQ (441)                                                                            | SOC (342)                | -death<br>-side effects<br>-death<br>-side effects<br>-death<br>-side effects<br>-death<br>-side effects | 8 days     |

http://mjiri.iums.ac.ir

Med J Islam Repub Iran. 2020 (17 Dec); 34.171.
### Characteristics of Randomized Clinical Studies

| Study first author, Country | Design | Setting | Participants | Interventions/Exposure (number of patients) | Comparison | Outcome | Follow-up |
|----------------------------|--------|---------|--------------|------------------------------------------|------------|---------|----------|
| Chen, Zh China | double blinded RCT | Inpatient | Hospitalized patients with RT-PCR confirmed COVID-19 Aged >18 years (Critical patients excluded) | Hydroxychloroquine oral 400mg daily between day 1 and 5 (31) | standard treatment (oxygen therapy, antiviral agents, antibacterial agents, and immunoglobulin, with or without corticosteroids (31)) only conventional treatment, including bed rest, oxygen inhalation, symptomatic support, antiviral therapy (14/15) | Changes in time to clinical recovery (TTCR) | Radiologic improvement | 5 days |
| Chen, J China | Pilot clinical trial | Inpatient | Hospitalized Patients with Covid-19 | Conventional treatment plus oral Hydroxychloroquine for 5 days (13/15) | | | | 14 days |
| Wei Tang China | Open-label randomized trial | Inpatient | patients with covid-19 infection confirmed by RT-PCR | Hydroxychloroquine oral 1200 mg daily for three days followed by 800 mg daily for remaining days which is either two or three weeks depending on the severity (75/150) | Only standard of care (75/150) | | SARS-CoV-2 RNA was assessed by real-time reverse transcription-PCR | 14 days |
| Borba, MGS Brazil | randomized, double-blinded, phase II clinical trial | Inpatient | Hospitalized patients diagnosed with severe respiratory syndrome resulting from Covid-19; clinically or PCR confirmed | Hydroxychloroquine oral/via an NG-tube 600mg twice daily for 10 days or a total of 12 gr +standard of care which included azithromycin | 450mg daily (only twice on the first day) or a total of 2.7g +standard of care which included azithromycin | | | 14 days |
| Cavalcanti, AB Brazil | multicenter, randomized, open-label, three-group, controlled trial | Inpatient | consecutive patients who were 18 years of age or older and who had been hospitalized with suspected or confirmed Covid-19 with 14 or fewer days since symptom onset | HCQ 400mg BD for 7 days (221) | SOC (229) | | | 15 days |
Appendix Table 2. Characteristics and Results of Animal Studies

| ID | First Author, study year | Interventions | Animal model | Virus model | Study design | Dosage-forms | Comparison | Number of subjects | Tissue | Length of follow-up | Outcomes | Results | Notes |
|----|--------------------------|---------------|--------------|-------------|-------------|--------------|------------|-------------------|--------|-------------------|----------|---------|-------|
| 1  | Dale L Barnard, 2006    | Amodiaquine; Chloroquine | Specific pathogen-free BALB/c female mice (11–18 g) | SARS-CoV-1 | 4h before the virus exposure. | Chloroquine was used at 50, 10, and 1 mg/kg intraperitoneally and intranasally; and Amodiaquine was used at 150, 75, and 10 mg/kg intranasally, and 75, 37.5, 18.8, and 9.4 mg/kg intraperitoneally; twice a day for 3 days. | PBS was used as placebo. | 15 mice per each concentration of the drugs used in the study | Lung | 3 days of the start of the treatment when virus was administered at 4 hours post treatment. | Virus titers (Duplicated Log10 CCID50/g) in homogenized lung tissue. | Chloroquine showed no effect on virus titers in vivo when used intraperitoneally. However, it had a statistically non-significant effect in reducing the virus titers in lung tissues. Amodiaquine had no effect at the highest concentration used in the study (15mg/kg) where it did not reduce the virus titers at lung tissues. | The efficiency of the drugs was also tested in vitro in African green monkey cells using different strains of the SARS-Cov including Urbani, Toronto 2, Frankfurt 1, CHUK-W1 strains and showed no effect for Chloroquine and two other salts of it but were blocked by Amodiaquine in vitro. Also, both drugs were claimed to be well tolerated but the data was not shown. |
| 2  | Els Keyaerts, 2009      | Chloroquine diphosphate | Newborn C57BL/6 mice; (El-evage Janvier, Le Genest Saint Isle, France) | Coronavirus OC43 (HCoV-OC43) | In the study two parts were included. 200μl of different dilutions of Chloroquine (corresponding to 1, 5 or 15 mg/kg of body weight) daily starting from 1 days before/after labor was administered subcutaneously. Subsequently, 5-day suckling mice were infected intracerebrally with virus containing 1x103 copy numbers of the virus genome and were followed for the outcome as death. The follow up study involved administering chloroquine at the high dose of 15 mg/kg prepartum and switch the litters for breast feeding. The same way the pups were infected, and the survival was followed for 60 days post-infection. A negative control group included no drug intervention. | Test Prepartum; Group 15mg/kg (9mothers[m]-70pups[p]), Group 5mg/kg (5m-42p), Group 1mg/kg (4m-21p). Test Postpartum; Group 15mg/kg (11m-76p), Group 5mg/kg (6m-42p), Group 1mg/kg (4m-31p). Group placebo (19m-132p). | No treatment | 9 mothers (m)-70 pups (p), 5m-42p, 4m-21p for different dose experiments. Test Postpartum groups 11m-76p, 6m-42p, 4m-31p for different drug concentrations. Group placebo 19m-132p. | Survival of the pups challenged with live virus 1000 TCID50 intracerebrally 5 days postpartum. | A log rank test indicated that the survival curve for litters that were treated prepartum with 15mg/kg chloroquine was significantly different from the survival curves for the pups that were treated prepartum with 5mg/kg (P= 0.0237), 1mg/kg (P= 0.0001). 100% survived treated 15 mg/kg prepartum (97.4% treated postpartum). The survival was dose dependent. The results of the follow-up study showed that switching the litters between groups of mothers to detect the effect of the transplacental or milk delivered chloroquine. The drug was effective when transferred by milk and not transplacentally. | The efficiency of the drug was also tested in vitro using HRT-18 cells and concentration higher than 0.16 μM results in a decline in the number of HCoV-OC43 copies determined by qRT-PCR. Additionally, the 15mg/kg drug group survived 100% when used prepartum meaning no adverse effect was associated with the usage of the drug in this study. |
**Appendix Table 3. Ctd.**

| ID  | First Author, study year | Interventions | Animal model | Virus model | Study design | Dosage-forms | Comparison | Number of subjects | Tissue | Length of follow-up | Outcomes | Results | Notes |
|-----|--------------------------|---------------|--------------|-------------|--------------|--------------|------------|-------------------|--------|-------------------|----------|---------|-------|
| 3   | Junwei Niu, 2020         | Chloroquine   | BALB/c mice (12-days old) | rOC43-ns2DelRluc replicative virus based on HCoV-OC43 virus. | Mice were inoculated with chloroquine and the virus then was administered intracerebrally at 100 TCID50 using rOC43-ns2DelRluc, and bioluminescence intensity was measured daily to quantify the virus replication. The tissues including brain and spinal cord were studied for the Photon flux and the presence of viral proteins by western blotting. | Chloroquine was administered to mice 2 h before viral inoculation (day 0; 30 mg/kg) and then administered daily according to a previous study of HCoV-OC43-WT (Keyaerts et al., 2009). | Drug to PBS as placebo | 3 mice in virus group and 3 mice in virus + drug group | Whole brain and spinal cord | 4 days post infection | Survival and the bioluminescence expressed by virus replication as well as the western blot analysis of the luciferase activity of the expressed protein in brain and spinal cord. | No signals were detected in mice treated with Chloroquine, and all of them survived, whereas all mice receiving PBS displayed increased bioluminescence and died, demonstrating a significant difference relative to the individual controls. Also, western blot analysis supported the data of the mice being successfully infected when virus was inoculated. | The main aim of the study was to optimize and validate the detection of the virus infection in mice and drug treatment was used as a control for the whole experiment. The initial dose of 30 mg/kg chloroquine has been reported to be toxic in C57BL/6 mice as reported above but was used in BALB/c mice in here followed by half dose thereafter. |